Shiela Plasencia, director of practice support at the Community Oncology Alliance, discusses the benefits of collecting social determinants of health data for both the patient and provider.
It is important to collect data to understand social determinants of health, but it can also be burdensome on the practices, says Shiela Plasencia, director of practice support, Community Oncology Alliance.
Transcript
What are the benefits of collecting data on social determinants of health versus the anticipated benefits for patients of collecting their data?
Yeah, so there's a lot of talk about that, I think the practices really understand that some of that health data is important. And it really impacts the outcomes that the patients will have as far as their treatment goes. But the practices don't really know how to go about doing that.
And what that communication is going to look like with the patient, it's really hard to garner that kind of trust with the patients, and then explain to the patients, what's going to be done with that data after we get this information from you, and make them feel secure that that data is going to be managed in a secure manner. And that they might, they just might not want to share that information.
And so there's a trusting relationship between the practice, the physicians, the nurses, and all of the people that work in the practice that take care of the patient. And if the patients think that they're giving this information, and you're going to turn it over to someone else, that kind of breaks down that trust a little bit. So I think there's a lot of kind of angst about what that's going to look like and how that's going to come to fruition. And what's going to happen with all that data.
When it comes to collecting SDOH [social determinants of health] data, can you discuss the balance between the burden of data collection on oncology practices vs the compensation the practices will receive?
Yeah, that's a great question. You know, the practices are already running very lean, they're still struggling with staffing, resources and issues, you know, from COVID. So in order to be able to assess the information that CMMI [CMS Innovation Center] is asking for, there's definitely going to have to be additional resources there. If you've got a social worker, one social worker is not going to probably be able to do all of that.
So what does that look like? And again, you've got a reduced MEOS [Monthly Enhanced Oncology Services payment]. So how do you go about, you know, beefing up your staffing to be able to commit to taking care of those social determinants of health issues with your patients, and build up the other necessary infrastructure that the practice needs to be able to be successful in that model.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
2 Commerce Drive
Cranbury, NJ 08512